Does Rallies show Form 4 insider transactions for RNA?

Yes. Rallies tracks RNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RNA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RNA. It does not provide personalized investment advice.

RNA (Atrium Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Atrium Therapeutics, Inc. Common Stock (RNA) is a publicly traded Healthcare sector company. As of May 21, 2026, RNA trades at $13.12 with a market cap of $221.52M and a P/E ratio of -2.56. RNA moved -1.81% today. Year to date, RNA is -82.36%; over the trailing twelve months it is -57.91%. Its 52-week range spans $11.95 to $73.06. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces RNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RNA stock inside the company?

Recent RNA insider activity includes Hughes Steven George sold 2.02K, Hughes Steven George sold 2.88K, Boyce Sarah sold 6.39K, Boyce Sarah sold 7.99K, and Flanagan W. Michael sold 3.98K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RNA Key Metrics

Key financial metrics for RNA
Metric	Value
Price	$13.12
Market Cap	$221.52M
P/E Ratio	-2.56
EPS	$-4.97
Dividend Yield	0.00%
52-Week High	$73.06
52-Week Low	$11.95
Volume	148.72K
Avg Volume	0
Revenue (TTM)	$18.75M
Net Income	$-684.63M
Gross Margin	0.00%

Recent RNA Insider Trades

Hughes Steven George sold 2.02K (~$146.13K) on Jan 21, 2026.
Hughes Steven George sold 2.88K (~$208.51K) on Jan 21, 2026.
Boyce Sarah sold 6.39K (~$463.25K) on Jan 21, 2026.
Boyce Sarah sold 7.99K (~$579.09K) on Jan 21, 2026.
Flanagan W. Michael sold 3.98K (~$288.06K) on Jan 21, 2026.

Latest RNA News

Atrium Therapeutics Posts $19.6M Q1 Revenue and Earns $15M BMS Milestone — May 14, 2026
Atrium Therapeutics Secures $15M Milestone, Opens $1.35B R&D and $825M Commercial Potential — Apr 23, 2026
Atrium Therapeutics Launches with $270M to Fund RNA Therapies for Rare Cardiomyopathies — Feb 27, 2026

RNA Analyst Consensus

2 analysts cover RNA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about RNA

Who is trading RNA stock inside the company?: Recent RNA insider activity includes Hughes Steven George sold 2.02K, Hughes Steven George sold 2.88K, Boyce Sarah sold 6.39K, Boyce Sarah sold 7.99K, and Flanagan W. Michael sold 3.98K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RNA?: Yes. Rallies tracks RNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RNA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RNA. It does not provide personalized investment advice.